Ghent University Academic Bibliography

Your filters: cql: author="Bex, Axel" or (type any "bookEditor issueEditor" and editor="Bex, Axel")

Add to list
- Journal Article
- A1
- open access
Update of the EORTC health-related quality of life modules for bladder cancer : phase 1–2 of the development process

Elke Rammant (UGent) , Louis Fox, Silva De Padova, Fredrik Liedberg, Lisa M. Wintner, Bernhard Holzner, Neil K. Aaronson, Katharina Beyer, Axel Bex, Otakar Čapoun, et al.

(2026) EUROPEAN UROLOGY ONCOLOGY. 9(3). p.645-651
Add to list
- Journal Article
- A1
- open access
Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma : insights from a European Delphi study

Viktor Grünwald, Axel Bex, Sylvie Rottey (UGent) , Cristina Suárez, Giuseppe Procopio, Guillermo Velasco, Bohuslav Melichar, Jens Bedke, Lisa Pickering, Mário Fontes-Sousa, et al.

(2025) EUROPEAN JOURNAL OF CANCER. 225.
Add to list
Cytoreductive nephrectomy and exposure to sunitinib : a post hoc analysis of the immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer (SURTIME) trial

Yasmin Abu‐Ghanem, Johannes V. Thienen, Christian Blank, Maureen J. B. Aarts, Michael Jewett, Igle Jan Jong, Jean‐Baptiste Lattouf, Harm H. E. Melick, Lori Wood, Peter Mulders, et al.

(2022) BJU INTERNATIONAL. 130(1). p.68-75
Add to list
European Association of Urology Guidelines Office Rapid Reaction Group : an organisation-wide collaborative effort to adapt the European Association of Urology guidelines recommendations to the coronavirus disease 2019 era

Maria J. Ribal, Philip Cornford, Alberto Briganti, Thomas Knoll, Stavros Gravas, Marek Babjuk, Christopher Harding, GORRG Grp, Alberto Breda, Axel Bex, et al.

(2020) EUROPEAN UROLOGY. 78(1). p.21-28
Add to list
Surgical safety of cytoreductive nephrectomy following sunitinib : results from the multicentre, randomised controlled trial of immediate versus deferred nephrectomy (SURTIME)

Roderick Emile De Bruijn, Peter Mulders, Michael A Jewett, John Wagstaff, Johan V Van Thienen, Christian U Blank, Roland Van Velthoven, Lori Wood, Harm E van Melick, Maureen J Aarts, et al.

(2019) EUROPEAN UROLOGY. 76(4). p.437-440
Add to list
Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib : the SURTIME randomized clinical trial

Axel Bex, Peter Mulders, Michael Jewett, John Wagstaff, Johannes V van Thienen, Christian U Blank, Roland van Velthoven, Maria del Pilar Laguna, Lori Wood, Harm HE van Melick, et al.

(2019) JAMA ONCOLOGY. 5(2). p.164-170
Add to list
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer

Kevin Sharpe, Grant D Stewart, Alan Mackay, Christophe Van Neste (UGent) , Charlotte Rofe, Dan Berney, Irfan Kayani, Axel Bex, Elaine Wan, Fiach C O'Mahony, et al.

(2013) CLINICAL CANCER RESEARCH. 19(24). p.6924-6934

Academic Bibliography

Update of the EORTC health-related quality of life modules for bladder cancer : phase 1–2 of the development process

Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma : insights from a European Delphi study

Cytoreductive nephrectomy and exposure to sunitinib : a post hoc analysis of the immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer (SURTIME) trial

European Association of Urology Guidelines Office Rapid Reaction Group : an organisation-wide collaborative effort to adapt the European Association of Urology guidelines recommendations to the coronavirus disease 2019 era

Surgical safety of cytoreductive nephrectomy following sunitinib : results from the multicentre, randomised controlled trial of immediate versus deferred nephrectomy (SURTIME)

Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib : the SURTIME randomized clinical trial

The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer

Contents

Support

Contact